POLYCYTHEMIA VERA

This study is testing an experimental drug called IMG-7289 for adults with two rare blood disorders where the body makes too many blood cells. It's for patients whose current standard treatments have stopped working or caused intolerable side effects. The main goal is to see if t…

This study is testing a combination of three drugs—azacitidine, venetoclax, and pevonedistat—for adults newly diagnosed with certain high-risk blood cancers. These include acute myeloid leukemia (AML) that developed from other blood disorders or prior cancer treatment, as well as…

This study allows patients who benefited from previous clinical trials of ruxolitinib (alone or with panobinostat) to continue receiving their treatment while researchers monitor long-term safety. The study includes 279 patients with various blood conditions like myelofibrosis an…

This early-stage study is testing an experimental drug called SLN124 in adults with polycythemia vera, a condition where the body makes too many red blood cells. The trial will first find a safe dose, then compare SLN124 against a placebo to see if it can reduce the need for bloo…

This study is testing if adding a new drug called veliparib to a standard two-drug chemotherapy works better for people with advanced blood cancers that have spread and are hard to treat. It will compare the two-drug combo with the three-drug combo in about 25 participants to see…

This study is testing a personalized plan to manage cytomegalovirus (CMV), a common and potentially serious infection, in patients who have received a donor stem cell transplant for blood cancers or disorders. The plan involves closely monitoring the virus level and the patient's…

This program provided access to the drug ruxolitinib for polycythemia vera patients who couldn't tolerate standard treatments. It was designed for compassionate use when other options had failed. The program is no longer accepting new patients.

This study is observing how well patients with polycythemia vera (a rare blood cancer) tolerate and respond to the drug ropeginterferon alfa-2b in real-world clinics, not a controlled trial. It aims to see how often the drug is prescribed, how many patients can stay on it, and it…

This study aims to identify warning signs that predict dangerous blood clots in people with a high-risk type of blood cancer called polycythemia vera. Researchers will observe 242 patients already on standard treatment for three years, tracking their health data to spot patterns …